U.S. markets close in 3 hours 27 minutes

EyePoint Pharmaceuticals, Inc. (EYPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.26+0.06 (+0.73%)
As of 12:30PM EDT. Market open.
Sign in to post a message.
  • A
    Alfred
    Two weeks to the next earnings call. We should see the stock price move up in advance of a good report. Hoping good news for a healthy increase in product sales.
  • S
    STEVE
    EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU
    Bullish
  • J
    Jennifer
    Online investment is very profitable I will recommend Bitcoin cause of it's high rate in stocks market if you should change that mindset of buying others coins and go for Bitcoin I will assure you that investors will kick up your trade from 2.1btc to 4.2btc with the help of Mrs Stephanie A. William I made my 5th withdrawal again trading with her and she listed Top5 coins someone have to buy and trade here are they coins she recommended to me below 👇

    1.Bitcoin(BTC) market cap:Over $641 billion.

    2.Ethereum (ETH) market cap:Over $307 billion.

    3.Tether (USDT) market cap:Over $62 billion.

    4.Binance coin (BNB) market cap:Over $56 billion.

    5.Cardano (ADA) market
    cap:Over $51 billion.

    Mrs Stephanie A. William is really recommended in today's marketing get in contact with her through 👇👇
    FB
    Stephanie A. William
  • s
    steve
    Wake up and finally see some good news on clinical trials for the company for wet AMD. Still have a long way to go but hoping for better news later on in the year.
  • R
    Richard S
    I owned shares here when there was 50 million shares outstanding. It is mind boggling that there are 287 million shares outstanding now. I sold at $10.10 after the reverse split. I put that money into another stock that has doubled. I believe this is one of the zombie companies that will never turn a profit and just keep diluting or selling off royalties. I have read that for every drug that undergoes clinical trials, only 1 in 10 will make it to Phase 3 and only 1 in 10 in Phase 3 will ever get approved. This company has no problem getting drugs approved, but their drugs don't sell. OCUL, which has also been getting hit hard, has already won the battle against Dexycu. Poor management here. They misled with revenue numbers that were not real. You had absolutely no idea how much they were selling and when they were selling. But in the end, they are not selling enough and now it all hinges on EYP-1901. The dream of Dexycu being a big seller is a nightmare.
  • S
    STEVE
    EyePoint Pharmaceuticals Joins Russell 2000 and Russell 3000 Index

    This will increase institutional buying. Moving on up.
    Bullish
  • S
    STEVE
    EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD

    http://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results
    Bullish
  • c
    cuban
    Once EYP1901 is over and done with this stock has the potential to reach $50 a share
    Bullish
  • S
    STEVE
    EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU Intraocular Suspension, Approved by the American Medical Association

    http://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code
    Bullish
  • G
    GIL
    this stock should be in 15-20 range, what's going on here ? didn't they sell 100mil @ 11$ a few months back?
  • M
    MICHAEL
    RV is on it's way...
  • M
    MICHAEL
    Here come dat ol' RV... Won't be long now...
  • M
    MICHAEL
    See my last post below...
  • S
    STEVE
    EYPT will see $20 by years end.
    Bullish
  • G
    Gary
    my small bioteches are not having good days ..sinking into the abyss... i guess they are just out of favor right now ..not sure why though ...low interest rates good for borrowing ...
  • S
    STEVE
    EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
    Bullish
  • s
    steve
    Steve W here. We are at the starting line for the one mile race with a long way to go to reach the tape and complete the run
  • S
    STEVE
    EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD
    Bullish
  • c
    charley
    $3 / all outstanding shares. That values the OSG company for less than 100 mil. That don't make sense.
    Finally get this dead horse out of the barn.